For the first time in alcohol addiction research, UVA investigators have successfully treated alcohol-dependent individuals with medication that is tailored specifically to match their genetic profile.
“Our findings suggest a new paradigm for the treatment of alcoholism, as well as a major breakthrough in individualized medicine for predetermined genotypes,” says Bankole Johnson, MD, PhD, study leader and professor and chair of the UVA Department of Psychiatry and Neurobehavioral Sciences.
The study, to be published in the March issue of the American Journal of Psychiatry and now available online, tested 283 genetically profiled alcoholics for the efficacy of ondansetron, a serotonin antagonist drug.
Previous research by UVA scientists has found that specified variations in the serotonin transporter gene, SLC6A4, play a significant role in influencing drinking intensity. Furthermore, past UVA research has identified ondansetron as a likely pharmaceutical target for serotonin-related genes.
Serotonin is a brain chemical that is involved in the regulation of pain perception, sleep, mood and other psychological processes. Studies have shown that serotonin mediates the rewarding effects of alcohol.
In this latest study, UVA researchers randomized alcoholics by genotype (LL vs. Sx and TT vs. Gx) in a controlled, double-blind clinical trial. Subjects received either ondansetron or placebo for 11 weeks, and all received standard cognitive behavioral therapy. A majority of subjects were white males, and more than 65 percent of subjects completed the study in its entirety. The study was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH). (View NIAAA press release).
Study findings show that ondansetron is indeed a promising therapeutic agent for the treatment of severe alcohol consumption among alcohol-dependent individuals with the predicted genetic marker – a marker that’s responsible for the amount of pleasure certain people may perceive while drinking or may perceive as a craving when they stop drinking, Johnson explains.
“The treatment response among those who received ondansetron was remarkable,” says Johnson. “What this tells us is that we have measurable evidence that personalized medicine is indeed a viable treatment for alcohol dependence.
The primary outcome tested by researchers involved ondansetron’s effects on the severity of alcohol consumption in selected alcohol-dependent individuals. The study was confined to one secondary variable – the percentage of days abstinent, in order to provide clinicians additional efficacy information. Study findings demonstrated a predicted therapeutic response to ondansetron, which increased the percentage of days abstinent relative to placebo for predetermined genotypes.
For men, who comprised 73 percent of all subjects, high-risk drinking of alcohol is defined as consuming five or more drinks per drinking day. This high risk has been associated with such severe health consequences as accidental injuries, deaths from external sources, aggression (both victim and perpetrator of), as well as numerous medical, legal and occupational problems.
For subjects with the LL/TT genotype, those treated with ondansetron, on average, fell below the high-risk drinking category, while those who received placebo remained in the high-risk category. In addition, these same genotype categories responded more positively to ondansetron, versus placebo, in increasing the days of abstinence.
The benefits of this type of personalized treatment approach are remarkably promising. Personalized medicine, or genome-based medicine, has the potential to give patient and their physicians the ability to make more informed treatment decisions.
“By being able to do genetic screening beforehand, clinicians can eliminate a great deal of the trial and error approach to prescribing medicine,” Johnson says. “Personalized medicine allows them to better predict a successful treatment option, as well as reducing both premature medication changes and simultaneous multiple medication regimens.”
Not all alcohol-dependent individuals are treated successfully with ondansetron.
“Although this treatment approach accounts for nearly one-third of patients with alcohol dependence, more research is needed to identify alcoholics with other genetic variations who will respond significantly to alternative medications,” says Johnson. “Our findings, however, are a major step into the forefront of modern medicine.”
For more information about addiction research at the UVA Health System, visit UVA Center for Addiction Research and Education (UVA CARE).
The Excelsior Program at the UVA Health System, founded by Dr. Johnson, is an individualized outpatient addiction treatment program that treats the whole person. It’s the first program of its kind to offer comprehensive and uniquely adaptive pharmacological and psychological treatment.
In a 2006 study published in the journal Drug and Alcohol Dependence, Dr. Johnson and UVA investigators found ondansetron to be a promising new treatment for some people addicted to cocaine.